Chagas Disease (American Trypanosomiasis) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chagas Disease (American Trypanosomiasis) – Pipeline Review, H2 2016’, provides an overview of the Chagas Disease (American Trypanosomiasis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)

The report reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chagas Disease (American Trypanosomiasis) therapeutics and enlists all their major and minor projects

The report assesses Chagas Disease (American Trypanosomiasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Eisai Co., Ltd.

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

KaloBios Pharmaceuticals, Inc.

Merck & Co., Inc.

Novartis AG

Sanofi

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chagas Disease (American Trypanosomiasis) Overview 9

Therapeutics Development 10

Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 10

Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 11

Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 12

Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 13

Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 17

Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 18

Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 19

Bayer AG 19

Eisai Co., Ltd. 20

GlaxoSmithKline Plc 21

Grupo Praxis Pharmaceutical SA 22

KaloBios Pharmaceuticals, Inc. 23

Merck & Co., Inc. 24

Novartis AG 25

Sanofi 26

Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

benznidazol - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

benznidazole - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

chagas disease (bivalent) vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

chagas disease vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

chagas disease vaccine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Chagas disease vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Cz-007 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Cz-008 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

EPLBS-1246 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

EPLBS-967 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

fexinidazole - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

fosravuconazole - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

GNF-6702 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

K-777 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

NEU-321 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

nifurtimox - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

nifurtimox SR - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

posaconazole - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SAR-114137 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules for Chagas Disease - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Small Molecules for Chagas Disease - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules for Chagas Disease - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecules for Chagas Disease - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecules for Chagas Disease - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules for Infectious Diseases - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules for Infectious Diseases - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules for Protozoal Infections - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

VNI - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Chagas Disease (American Trypanosomiasis) - Dormant Projects 72

Chagas Disease (American Trypanosomiasis) - Discontinued Products 73

Chagas Disease (American Trypanosomiasis) - Product Development Milestones 74

Featured News & Press Releases 74

Apr 11, 2016: KaloBios Announces New Product Pricing Model 74

Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease 74

May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease 75

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 76

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 77

May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world 78

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 79

Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2016 10

Number of Products under Development for Chagas Disease (American Trypanosomiasis) – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Chagas Disease (American Trypanosomiasis) – Pipeline by Bayer AG, H2 2016 19

Chagas Disease (American Trypanosomiasis) – Pipeline by Eisai Co., Ltd., H2 2016 20

Chagas Disease (American Trypanosomiasis) – Pipeline by GlaxoSmithKline Plc, H2 2016 21

Chagas Disease (American Trypanosomiasis) – Pipeline by Grupo Praxis Pharmaceutical SA, H2 2016 22

Chagas Disease (American Trypanosomiasis) – Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 23

Chagas Disease (American Trypanosomiasis) – Pipeline by Merck & Co., Inc., H2 2016 24

Chagas Disease (American Trypanosomiasis) – Pipeline by Novartis AG, H2 2016 25

Chagas Disease (American Trypanosomiasis) – Pipeline by Sanofi, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Chagas Disease (American Trypanosomiasis) – Dormant Projects, H2 2016 72

Chagas Disease (American Trypanosomiasis) – Discontinued Products, H2 2016 73

List of Figures

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2016 10

Number of Products under Development for Chagas Disease (American Trypanosomiasis) – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports